Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification.

MLA

Zeng, Peter Y. F., et al. “Immune-Based Classification of HPV-Associated Oropharyngeal Cancer with Implications for Biomarker-Driven Treatment de-Intensification.” EBioMedicine, vol. 86, Dec. 2022, p. 104373. EBSCOhost, https://doi.org/10.1016/j.ebiom.2022.104373.

APA

Zeng, P. Y. F., Cecchini, M. J., Barrett, J. W., Shammas-Toma, M., De Cecco, L., Serafini, M. S., Cavalieri, S., Licitra, L., Hoebers, F., Brakenhoff, R. H., Leemans, C. R., Scheckenbach, K., Poli, T., Wang, X., Liu, X., Laxague, F., Prisman, E., Poh, C., Bose, P., … Nichols, A. C. (2022). Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. EBioMedicine, 86, 104373. https://doi.org/10.1016/j.ebiom.2022.104373

Chicago

Zeng, Peter Y F, Matthew J Cecchini, John W Barrett, Matthew Shammas-Toma, Loris De Cecco, Mara S Serafini, Stefano Cavalieri, et al. 2022. “Immune-Based Classification of HPV-Associated Oropharyngeal Cancer with Implications for Biomarker-Driven Treatment de-Intensification.” EBioMedicine 86 (December): 104373. doi:10.1016/j.ebiom.2022.104373.